Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Rheos Medicines Inc.
Headquarters: Cambridge, MA, United States of America
Website: N/A
Year Founded: 2016
Status: Out of Business
BioCentury | Feb 12, 2025
Management Tracks
New CEOs at Aro and Navigator
Plus: Arbuckle retiring from Vertex, and updates from Lb, Glox, Titan and more
BioCentury | Sep 13, 2024
Finance
Trio of first-day pops may bode well for biotech IPO window
With three biotechs trading up after NASDAQ debuts, sustained positive performance could further open window
BioCentury | Aug 26, 2024
Finance
Three’s a crowd? MBX follows Bicara, Zenas into IPO queue
Indiana-based developer of long-acting peptide therapeutics is latest mid-to-late-stage biotech to seek NASDAQ listing
BioCentury | Aug 24, 2024
Finance
Public Equity Report: Signs of life for biotech IPOs as Zenas, Bicara file, TYK sticks landing
Pair of well-funded late-stage biotechs seek NASDAQ listings, Shanghai cancer company prices deal in Hong Kong
BioCentury | Jul 3, 2024
Management Tracks
Dahan succeeds Saad as Alkeus CEO
Plus: Fox becomes interim CEO of Alphina and updates from Inovio and BenevolentAI
BioCentury | Apr 25, 2023
Management Tracks
Sanofi’s Silvestri joins Ipsen as CMO
Plus: Malier leaving Kurma and updates from Harmony, ImmunoGen, Tarsus and more
BioCentury | Oct 6, 2022
Management Tracks
J&J’s Kumar becomes Cure’s CEO
Plus Shanton recruits LianBio’s Li and updates from BlueSphere, Valence and Apnimed
BioCentury | May 13, 2022
Discovery & Translation
Aro’s protein-siRNA conjugate for Pompe disease; plus Rheos, Mozart and more
BioCentury’s roundup of translational news
BioCentury | Apr 15, 2022
Management Tracks
Sarepta veteran O’Neill becomes CEO at Editas
Plus Slapak retires from Vor, and updates from Harbour, Citius and more
BioCentury | Aug 10, 2021
Management Tracks
Bogle replaces Bazemore as CEO at Epizyme
Plus: Updates from AltruBio, Sutro, Rheos, Affinivax and more
Items per page:
1 - 10 of 20